收藏切换
Progress in clinical research of subcutaneous immunoglobulin
收藏切换
Zhilong LAN1, Lei WANG2, Song ZHANG2, Zhihui LI2, Junlong WANG1, *, Na NI1, *
World Clinical Drug | 2024, 45(7) : 794 - 798
Less
收藏切换
World Clinical Drug | 2024, 45(7): 794-798
• Review •
Progress in clinical research of subcutaneous immunoglobulin
Full
Zhilong LAN1, Lei WANG2, Song ZHANG2, Zhihui LI2, Junlong WANG1, *, Na NI1, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China
Published: 2024-07-10 doi: 10.13683/j.wph.2024.07.016
Outline
收藏切换

Immunoglobulin is recognized to be used for the treatment of various diseases, not only because it can serve as an alternative therapy against infections, but also because of its immunomodulatory effects. Appropriate use of immunoglobulins can save lives. However, its route of administration may lead to many adverse events and potential other adverse consequences. At present, intravenous immunoglobulin is the main clinical use in China, but there are more adverse events in the process of clinical use, and the patient compliance is not high. Due to this unmet clinical need, subcutaneous immunoglobulin (SCIg) has been developed abroad, which has been used in multiple clinical indications. However, SCIg in China is still in the early stage of exploration and research and development. Faced with the huge clinical needs in China, domestic blood product research and development companies have been encouraged to accelerate the research and development of SCIg drugs of different specifications and different indications to meet the treatment needs of domestic patients. This article reviewed the latest clinical research progress of SCIg in the treatment of primary immunodeficiency diseases, autoimmune neuromuscular diseases and other rare diseases, in order to provide new research and development ideas and suggestions for blood product research and development enterprises in China.

subcutaneous immunoglobulin  /  primary immunodeficiency diseases  /  autoimmune neuromuscular diseases  /  rare diseases
兰志龙, 王磊, 张松, 李智慧, 王俊龙, 倪娜. 皮下注射人免疫球蛋白药物的临床研究进展. 世界临床药物, 2024 , 45 (7) : 794 -798 . DOI: 10.13683/j.wph.2024.07.016
Zhilong LAN, Lei WANG, Song ZHANG, Zhihui LI, Junlong WANG, Na NI. Progress in clinical research of subcutaneous immunoglobulin[J]. World Clinical Drug, 2024 , 45 (7) : 794 -798 . DOI: 10.13683/j.wph.2024.07.016
Year 2024 volume 45 Issue 7
14
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.07.016
  • Receive Date:2024-01-12
  • Online Date:2026-11-17
  • Published:2024-07-10
Article Data
Affiliations
History
  • Received:2024-01-12
Affiliations
    1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
    2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.07.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT